Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA by Year
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — U.S. sales ($M) ($M)
Johnson & Johnson INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA: $2,725M in FY2025, down 12.8% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-11) ↗
Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 2,725 | -12.8% | Form 10-K (filed 2026-02-11) ↗ |
| FY2024 | Dec 29, 2024 | 3,125 | +7.9% | Form 10-K (filed 2026-02-11) ↗ |
| FY2023 | Dec 31, 2023 | 2,897 | +6.7% | Form 10-K (filed 2026-02-11) ↗ |
| FY2022 | Jan 1, 2023 | 2,714 | +6.4% | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Jan 2, 2022 | 2,550 | +10.2% | Form 10-K (filed 2024-02-16) ↗ |
| FY2020 | Jan 3, 2021 | 2,314 | +9.8% | Form 10-K (filed 2023-02-16) ↗ |
| FY2019 | Dec 29, 2019 | 2,107 | +17.6% | Form 10-K (filed 2022-02-17) ↗ |
| FY2018 | Dec 30, 2018 | 1,791 | +12.6% | Form 10-K (filed 2021-02-22) ↗ |
| FY2017 | Dec 31, 2017 | 1,590 | +18.4% | Form 10-K (filed 2019-02-20) ↗ |
| FY2016 | Jan 1, 2017 | 1,343 | – | Form 10-K (filed 2019-02-20) ↗ |
Breakdown
What makes up INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
Cite this data
StockData. (2026). Johnson & Johnson INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA ($M), annual FY2016–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-invega-us
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.